Garcia Christine A, Wu Shenhong
a Division of Hematology/Oncology, Department of Medicine , University of Pittsburgh Medical Center , Pittsburgh , Pennsylvania , USA.
b Division of Hematology/Oncology, Department of Medicine , Stony Brook University Hospital , Stony Brook , New York , USA.
Cancer Invest. 2016 Nov 25;34(10):521-530. doi: 10.1080/07357907.2016.1242009. Epub 2016 Oct 28.
The risk of infection attributable to mTOR inhibitors has not been determined. Databases from PubMed and abstracts presented at the American Society of Clinical Oncology meetings were searched. Eligible studies included randomized controlled trials, in which everolimus or temsirolimus was compared with placebo. A total of 12 trials were included. The attributable incidences of all-grade and high-grade infections to mTOR inhibitors were 9.3% (95% confidence interval (CI): 5.8-14.6%) and 2.3% (95% CI: 1.2-4.4%) respectively. The risk varied widely with tumor types (p <.001). There was substantial risk of infection attributable to mTOR inhibitors everolimus and temsirolimus.
mTOR抑制剂所致感染风险尚未确定。检索了来自PubMed的数据库以及在美国临床肿瘤学会会议上发表的摘要。符合条件的研究包括随机对照试验，其中将依维莫司或替西罗莫司与安慰剂进行比较。共纳入12项试验。mTOR抑制剂所致全级和高级别感染的归因发病率分别为9.3%（95%置信区间（CI）：5.8 - 14.6%）和2.3%（95%CI：1.2 - 4.4%）。风险因肿瘤类型而异（p <.001）。mTOR抑制剂依维莫司和替西罗莫司存在显著的感染风险。
